NBTX Nanobiotix Group Company Short-Term Debt

Nanobiotix - graphic logo of issuer NBTX

This daily price chart for Nanobiotix S.A. (NBTX) on GURU.Markets reflects the quotes of a brand with a powerful scientific standing in nanomedical oncology solutions, where the indicator stands at 0.00. The development of radiation-enhancing drugs is accelerating through AI modeling, although final trials require medical supervision. A stable staff of scientists from the US and France is currently being strategically supplemented by clinical engagement experts.

NBTX nanobiotix.com Short-Term Debt (07/04/2022 - 10/31/2026)

Analytical breakdowns and data insights for company Nanobiotix Group (NBTX)

- current quotes and average value forecast:
Price Chart Nanobiotix|NBTX - Average Forecast Price
- market capitalization data:
Market Value Nanobiotix S.A.|NBTX - Total Company Value
- shareholders' equity book value data:
Net Assets per Single Share Nanobiotix|NBTX - Total Stockholders' Equity|Market Capitalization to Book Value Ratio nanobiotix.com|NBTX - Company Balance Sheet Assets
- company total debt and liquidity indicators:
Total Debt to Equity Ratio Nanobiotix S.A.|NBTX - Long-Term Liabilities to Capital|Short-Term Debt to Equity Ratio Nanobiotix S.A.|NBTX - Aggregate Debt Obligations|Debt to Book Capitalization Ratio Nanobiotix S.A.|NBTX - Long-Term Liabilities|Company Short-Term Debt Nanobiotix|Quick Ratio nanobiotix.com
- earnings and multiples data:
NBTX - Net Profit
General company analysis:NBTX - Nanobiotix
Flagship merchandise of nanobiotix.com

Nanobiotix S.A. (NBTX) focuses on high-cost R&D developments of oncology platforms, relying on external financing. Short-term debts quantify current liabilities, reflecting the company's ability to service loans within a year. This metric measures liquidity and default risk in the absence of operating revenue. Daily monitoring allows for the separation of technical fluctuations from systemic debt growth. Analyzing the company's short-term credits and loans protects the investor from erroneous decisions based on one-off spikes.

Key competitors

GERN - Company Short-Term Debt|Short-Term Debt Bicycle Therapeutics PLC|CytomX Therapeutics Inc (CTMX) - Company Short-Term Debt|CATX (Perspective Therapeutics, Inc.) - Company Short-Term Debt|Company Short-Term Debt Genelux Corp.|Short-Term Debt Molecular Partners Ltd MOLN|Company Short-Term Debts ONCY|lisata.com (LSTA) - Short-Term Indebtedness|Moleculin Biotech - Company Current Liabilities|Galera Therapeutics Inc. (GRTX) - Short-Term Debt|MTEM: Company Current Liabilities